Nektar Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants

NEKTAR THERAPEUTICS

Offering of 6,603,449 common shares at $58.00 and 293,103 pre-funded warrants at $57.9999; gross proceeds $400M.
Underwriters exercised full option for 1,034,482 additional shares; net proceeds ~$432M after discounts/expenses.
Proceeds for general corporate purposes including Phase 3 trial for rezpegaldesleukin and manufacturing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEKTAR THERAPEUTICS entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. valued at approximately 432.0 million (effective 2026-02-11).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co.
Value: approximately 432.0 million
Effective: 2026-02-11

Exact text from the filing

On February 11, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”)

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001193125-26-049378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.